Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GYRE Gyre Therapeutics	$8.09 +0.7%	$9.10	$6.11 ▼ $19.00	$749.12M	1.79	123,915 shs	86,117 shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
OGN Organon & Co.	$9.87 -3.2%	$10.00	$8.01 ▼ $23.10	$2.61B	0.58	3.43 million shs	2.97 million shs
SWTX SpringWorks Therapeutics	$46.86 0.0%	$44.48	$28.21 ▼ $62.00	$3.53B	0.7	2.41 million shs	4.19 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GYRE Gyre Therapeutics	+0.75%	-10.11%	-28.72%	-21.30%	-29.84%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	+3.61%
OGN Organon & Co.	-3.31%	-1.69%	+9.32%	-37.58%	-51.50%
SWTX SpringWorks Therapeutics	-0.02%	+0.26%	+1.63%	-7.45%	+27.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GYRE Gyre Therapeutics	0.3318 of 5 stars	0.0	3.0	0.0	0.0	2.1	0.8	0.0
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	4.567 of 5 stars	3.3	2.0	1.7	3.7	1.7	3.3	1.9
SWTX SpringWorks Therapeutics	1.5644 of 5 stars	3.1	2.0	0.0	0.0	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
MOR MorphoSys	0.00	N/A	N/A	N/A
OGN Organon & Co.	2.50	Moderate Buy	$18.00	82.46% Upside
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	12.19% Upside

Current Analyst Ratings Breakdown

Latest GYRE, OGN, MOR, and SWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/12/2025	SWTX SpringWorks Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$47.00 ➝ $47.00
5/5/2025	OGN Organon & Co.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $10.00
5/2/2025	OGN Organon & Co.	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline
4/30/2025	SWTX SpringWorks Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$74.00 ➝ $47.00
4/29/2025	SWTX SpringWorks Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
4/29/2025	SWTX SpringWorks Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$66.00 ➝ $47.00
4/28/2025	SWTX SpringWorks Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$77.00 ➝ $47.00
4/28/2025	SWTX SpringWorks Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/28/2025	SWTX SpringWorks Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$63.00 ➝ $47.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GYRE Gyre Therapeutics	$105.76M	7.17	$0.20 per share	40.46	$1.05 per share	7.70
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
OGN Organon & Co.	$6.40B	0.40	$4.84 per share	2.04	$1.83 per share	5.39
SWTX SpringWorks Therapeutics	$219.67M	16.07	N/A	N/A	$6.47 per share	7.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GYRE Gyre Therapeutics	$12.09M	$0.02	404.70	∞	N/A	7.20%	9.73%	7.66%	8/12/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
OGN Organon & Co.	$864M	$2.88	3.43	2.64	1.08	11.92%	227.43%	7.34%	8/5/2025 (Estimated)
SWTX SpringWorks Therapeutics	-$258.13M	-$3.41	N/A	N/A	N/A	-115.60%	-51.10%	-43.80%	8/6/2025 (Estimated)

Latest GYRE, OGN, MOR, and SWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	GYRE Gyre Therapeutics	$0.03	$0.03	N/A	N/A	$28.40 million	$22.06 million
5/9/2025	Q1 2025	SWTX SpringWorks Therapeutics	-$0.81	-$1.11	-$0.30	-$1.11	$64.19 million	$49.09 million
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.81%	N/A	2.78%	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest GYRE, OGN, MOR, and SWTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GYRE Gyre Therapeutics	N/A	3.60	3.19
MOR MorphoSys	4.98	1.38	1.38
OGN Organon & Co.	16.49	1.67	1.15
SWTX SpringWorks Therapeutics	N/A	4.33	4.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GYRE Gyre Therapeutics	23.99%
MOR MorphoSys	18.38%
OGN Organon & Co.	77.43%
SWTX SpringWorks Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
GYRE Gyre Therapeutics	10.00%
MOR MorphoSys	0.05%
OGN Organon & Co.	1.40%
SWTX SpringWorks Therapeutics	7.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GYRE Gyre Therapeutics	40	93.76 million	84.38 million	No Data
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
OGN Organon & Co.	4,000	259.96 million	256.32 million	Not Optionable
SWTX SpringWorks Therapeutics	230	75.35 million	69.45 million	Optionable

GYRE, OGN, MOR, and SWTX Headlines

Recent News About These Companies

Comparing SpringWorks Therapeutics (NASDAQ:SWTX) & Genenta Science (NASDAQ:GNTA)

June 18 at 2:54 AM | americanbankingnews.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Hold" by Analysts

June 17 at 3:14 AM | marketbeat.com

Biotech Stocks To Consider - June 16th

June 16 at 2:11 PM | marketbeat.com

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading Volume - Here's Why

June 16 at 1:21 PM | marketbeat.com

FNY Investment Advisers LLC Purchases New Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 16 at 7:44 AM | marketbeat.com

Assenagon Asset Management S.A. Takes $3.52 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 16 at 3:56 AM | marketbeat.com

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase - What's Next?

June 9, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Squarepoint Ops LLC

June 5, 2025 | marketbeat.com

RFG Advisory LLC Takes $3.93 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 4, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 19,315 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 4, 2025 | marketbeat.com

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

June 3, 2025 | businesswire.com

Nuveen Asset Management LLC Has $6.64 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 31, 2025 | marketbeat.com

BNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 28, 2025 | marketbeat.com

SpringWorks Therapeutics (SWTX) Surged on Acquisition News

May 27, 2025 | msn.com

SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges

May 27, 2025 | investing.com

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

May 26, 2025 | zacks.com

ProShare Advisors LLC Has $827,000 Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 26, 2025 | marketbeat.com

Deutsche Bank AG Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 25, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of "Hold" from Analysts

May 25, 2025 | marketbeat.com

Palisades Investment Partners LLC Buys 12,154 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 24, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Bank of America Corp DE

May 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy
By Chris Markoch | May 29, 2025
View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy
3 Stocks Set to Double—And There's Still Time to Buy
By Nathan Reiff | June 12, 2025
View 3 Stocks Set to Double—And There's Still Time to Buy
Tesla: Why Analysts Think It Could Jump Another 47%
By Sam Quirke | May 27, 2025
View Tesla: Why Analysts Think It Could Jump Another 47%
Best Value Stocks According to Morningstar in 2025
By Gabriel Osorio-Mazilli | May 19, 2025
View Best Value Stocks According to Morningstar in 2025

GYRE, OGN, MOR, and SWTX Company Descriptions

Gyre Therapeutics NASDAQ:GYRE

$8.09 +0.06 (+0.75%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$8.07 -0.02 (-0.19%)

As of 06/17/2025 04:04 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 06/16/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Organon & Co. NYSE:OGN

$9.86 -0.33 (-3.19%)

Closing price 06/17/2025 03:59 PM Eastern

Extended Trading

$9.89 +0.03 (+0.25%)

As of 04:35 AM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

SpringWorks Therapeutics NASDAQ:SWTX

$46.86 -0.01 (-0.02%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$46.85 -0.01 (-0.02%)

As of 06/17/2025 06:59 PM Eastern

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time